Merck leapfrogs rivals in lung cancer drug combination race

Merck & Co has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer, potentially giving it a major lift in the battle for the largest cancer market. U.S. regulators have agreed to a speedy review of Merck’s application to combine its immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer, the U.S. drugmaker said. Merck said the U.S. Food and Drug Administration (FDA) would decide by May 10 whether to approve its Keytruda combination treatment, sending the company’s stock 5 percent higher in early U.S. trading on Wednesday.
Go to Source

Ryan: Obamacare repeal to have transition time, replacement

Ryan holds a news conference at the U.S. Capitol in WashingtonWASHINGTON (Reuters) – U.S. House Republicans&; efforts to repeal Obamacare will include a "stable transition period" as well as a plan to replace President Barack Obama&039;s signature health care law, House Speaker Paul Ryan told reporters on Tuesday. Ryan, speaking at a press conference, said House lawmakers will pass whatever they can on a health care replacement plan through the reconciliation and budget bill, then use a regular legislative process for additional measures. (Reporting by Lisa Lambert; Writing by Susan Heavey)

Go to Source

1 2 3 5,952